. Author manuscript; available in PMC: 2008 Dec 10.

Published in final edited form as: Proteomics Clin Appl. 2008 Sep;2(9):1265–1280. doi: 10.1002/prca.200800017

Table 3.

Expression of candidate maker proteins in vitretional diseases. The value x, as represented by “+”, denotes the fold-indicate of each protein compared to control. The candidate marker proteins that are ranked higher then 10^th in Fig. 6 are indicated by “+”. The asterisk (*) indicates the ranking of some notable proteins in their signal to noise (S2N) values.

	NPDR	PDR	RRD	PVR
AAT	+	+	+	++
APOA4	+	+	+	++
ALB	+	+	*33^rd (+++)	++
TF	+	*11^th (+)	*35^th (++)	++
A1BG	+	+
C3	+++++(52-fold); +	+
FGG	++	+++++(173-fold); +
GC	+	+
APOA1	++
AZGP1		+		+
PEDF			++; +; +++; ++	+
CLU			++++	22^nd; 24^th; *28^th (al ++)
CTSD			+++; +++; +++
TTR			23^rd; 28^th (both++)	+
RBP4				++
SERPINC1				++

Fold-increase compared to control:

+; 3≤x<10

++; 10≤x<20

+++; 20≤x<30

++++; 30≤x<40

+++++; larger then 40-fold (shown in parenthesis)

FGB was detecated in all NPDR samples (12/12) in contrast to fibrin beta (5/12).

FGB was detecated in 11/16 PDR samples (12/12) in contrast to fibrin beta (6/16).